Lack of appropriate biophysical cues within commercial activation reagents and processes increases the risk of generating suboptimal cell populations, which can have implications for inefficient cell activation, higher cost of treatment, increased vein-to-vein time, and reduced functionality of cells in vivo.
Create a single, modular, and scalable platform capable of both biophysical and flow enhancements for promoting the activation, proliferation, and transduction of T-cells, with opportunities for selection and integration.
Develop an innovative technology platform for cell therapy manufacturing that can accommodate all the necessary unit operations, including separation of cell phenotypes, activation and transduction, and expansion of purified phenotypes
Integration of tailorable soft materials that will provide optimal microenvironments to facilitate and control cell capture, release, manipulation, and promotion of desired functions
Bomb, K., LeValley, P. J., Woodward, I. R., Cassel, S. E., Sutherland, B. P., Bhattacharjee, A., Yun, Z., Steen, J., Kurdzo, E., McCoskey, J., Burris, D., Levine, K., Carbrello, C., Lenhoff, A. M., Fromen, C. A., & Kloxin, A. M. (2023). Cell Therapy Biomanufacturing: Integrating Biomaterial and Flow-Based Membrane Technologies for Production of Engineered T-Cells. Advanced Materials Technologies, 8(6). https://doi.org/10.1002/admt.202201155
Lopez Ruiz, A., Slaughter, E. D., Kloxin, A. M., & Fromen, C. A. (2024). Bridging the gender gap in autoimmunity with T-cell-targeted biomaterials. Current Opinion in Biotechnology, 86. https://doi.org/10.1016/j.copbio.2024.103075
Login to the NIIMBL member portal to access more, including:
Not yet a member? Learn more about which level of NIIMBL membership is right for you and your organization.
University of Delaware
Merck Sharp & Dohme LLC
MilliporeSigma/EMD Serono
